Dermatology Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization: A Complete Patient Guide

Prior authorization (PA) for dermatology treatments has become one of the most burdensome aspects of skin care in the United States. Biologics for psoriasis, eczema, and hidradenitis suppurativa, phototherapy, specialty procedures, and even some diagnostic tests now require advance insurance approval before treatment can begin. This guide explains the PA process, why denials happen, and how to build a successful appeal.

Why Prior Authorization Is So Common in Dermatology

Dermatology has become one of the most PA-burdened specialties because:

• Biologics are expensive: Psoriasis and atopic dermatitis biologics cost $20,000–$60,000 per year. Payers use PA to ensure step therapy compliance and formulary steerage.
• eviCore manages many dermatology PAs: Many commercial insurers outsource dermatology and specialty pharmacy PA to eviCore healthcare, a benefits management company. Understanding eviCore's specific criteria is essential.
• Multiple PA systems: Pharmacy and medical benefit PAs may be handled by different departments with different criteria — creating confusion and duplicate denials.
• Formulary changes: Annual formulary changes may require new PAs for existing medications, disrupting stable patients.

The Most Common Dermatology Denial Reasons

1. Step therapy not completed: The most common reason. The insurer requires failure on cheaper alternatives before approving the requested treatment.

2. Severity not established: Insufficient objective documentation — PASI, EASI, DLQI, IGA, SCORAD, HDSS, SALT, or Hurley staging — in the PA submission.

3. Non-formulary medication: The specific biologic or medication requested is not on the formulary; a different agent in the same class is preferred.

4. Incomplete submission: Missing clinical notes, incomplete prior therapy history, or absent physician attestation forms.

5. Wrong benefit (pharmacy vs. medical benefit): Infused or in-office administered biologics may need to go through the medical benefit rather than pharmacy benefit, with different PA requirements.

6. Coding mismatch: The diagnosis code submitted doesn't match the approved indication for the medication.

The eviCore Dermatology PA Program

eviCore manages dermatology PA for many Blue Cross Blue Shield plans, United Healthcare, Aetna, and Cigna plans. When your PA is being reviewed by eviCore:

• Use their clinical criteria directly: eviCore publishes its clinical criteria for dermatology PAs online. Download the relevant criteria document and ensure your submission addresses every point.
• Submit objective severity scores: eviCore PA reviewers are trained to look for PASI/BSA/DLQI for psoriasis, EASI/IGA for atopic dermatitis, HDSS for hyperhidrosis, and Hurley staging for HS. Missing scores are the single most common reason for eviCore denial.
• Include the complete medication history: List every prior treatment with start date, dose, duration, and specific reason for discontinuation.
• Request peer-to-peer early: eviCore offers peer-to-peer review within 2 business days of denial. Your dermatologist should request this immediately upon denial — it is substantially more successful than written appeals alone.

Peer-to-Peer Review: Your Most Powerful Tool

A peer-to-peer review is a telephone consultation between your dermatologist and the insurance company's (or eviCore's) medical director or reviewing physician. Peer-to-peer reviews have significantly higher success rates than written appeals for dermatology cases because:

• Dermatologist-to-physician communication allows clinical nuance that documents cannot capture
• Reviewers are more likely to reverse decisions when speaking directly with the treating specialist
• Your dermatologist can explain why standard step therapy criteria don't apply to your specific case

To request a peer-to-peer:

1. Ask your dermatologist's office to call the insurer or eviCore immediately upon denial
2. Request the callback within the standard timeframe (typically 2 business days)
3. Prepare a concise summary of the clinical case, severity scores, and step therapy history for the call
4. Document the outcome of the peer-to-peer in writing afterward

AAD Evidence-Based Guidelines: How to Cite Them

The American Academy of Dermatology publishes clinical practice guidelines (CPGs) for major skin conditions. In appeal letters, cite guidelines specifically:

• Use the AAD guideline title, publication year, and journal citation
• Reference the specific recommendation and strength of evidence (Level A, B, or C; Grade of Recommendation)
• Quote the relevant sentence or paragraph directly in your appeal letter
• Argue that treatment consistent with national clinical guidelines published by the specialty's leading professional organization meets the standard of care

Guidelines are available free at aad.org/professionals/clinical-care/clinical-guidelines. For conditions like psoriasis, atopic dermatitis, HS, and ACD, highly specific, evidence-based recommendations are available.

Writing a Winning Dermatology Appeal Letter

A complete dermatology PA appeal letter should include:

1. Patient demographics and insurance ID
2. Requested treatment with drug name, dose, and route
3. Specific denial reason being addressed
4. Objective severity documentation (scoring tools)
5. Complete prior therapy history with failure documentation
6. FDA labeling for the requested treatment
7. AAD/specialty society guideline citations
8. Physician attestation of medical necessity
9. Statement of clinical urgency if applicable

Fight Back With ClaimBack

ClaimBack automates dermatology appeal letter generation, incorporating eviCore criteria compliance, AAD guideline citations, and severity scoring frameworks for every major skin condition.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied